No Detail Found!

Simultaneous Chromatographic Determination of Multi Drug Components in Fixed Dose Combination Tablets Containing Olmesartan, Hydrochlorothiazide and Amlodipine

Author(s)
Syed Muhammad Imran Department of Biochemistry, University of Karachi, Karachi, Pakistan.
Tariq Ali Department of Pharmaceutics, Faculty of Pharmaceutical Sciences, Dow University of Health Sciences, Karachi, Pakistan.
Madiha Maboos Department of Pharmaceutics, Faculty of Pharmacy, Iqra University, Karachi, Pakistan.
Fahad Siddiqui Department of Pharmaceutics, Faculty of Pharmacy & Pharmaceutical Sciences, University of Karachi, Karachi, Pakistan.
Muhammad Talha Usmani Department of Pharmaceutics, Faculty of Pharmacy & Pharmaceutical Sciences, University of Karachi, Karachi, Pakistan.
Abstract
Background: A number of pharmaceutical companies manufacture fixed-dose combination tablets containing Olmesartan, Hydrochlorothiazide and Amlodipine, while few analytical methods are available for simultaneous determination of the three compounds. The existing methods are more time consuming and possess less sensitivity. Objective: The objective of the study was to develop a sensitive, precise and accurate reverse phase high performance liquid chromatographic method for simultaneous quantification of olmesartan, hydrochlorothiazide and amlodipine in tablet dosage form and validate it as per international regulatory guidelines. Methodology: The analytes were separated using a C-18 (25cm×4.6mm, 5µm) reverse phase column using mobile phase consisting of tri-ethylamine in water adjusted to pH 2.75 with o-Phosphoric acid and Acetonitrile (69:31) (Buffer: ACN) v/v pumped at a flow rate of 1.0 mL/min with an injection volume of 20µl. Results: Linearity was found within the range 8.05-60.42 µg/mL (R2=0.9991) for olmesartan, 4.99-37.46 µg/mL and for hydrochlorothiazide (R2=0.9980) and 1.98-14.87 µg/mL for amlodipine (R2=0.9997). The system suitability parameters as well as robustness were found acceptable with %RSD < 2.0. The percentage recovery of three analytes was 98.841 ± 0.401, 99.672 ± 0.563 and 98.865 ± 0.521 at 100% of nominal concentration for olmesartan, hydrochlorothiazide and amlodipine respectively. Conclusion: A new UV-HPLC based analytical method for simultaneous quantification of Olmesartan, Hydrochlorothiazide and Amlodipine has been successfully developed and and validate it according to international regulatory guidelines. The method can be effectively applied for the assay of tablets in pharmaceutical QC labs.
Publication Details
Page(s) 170-177
DOI DOI not available
Published Journal: RADS Journal of Pharmacy and Allied Health Sciences, Volume: 2, Issue: 4, Year: 2024

Request the full text from PASTIC

Keywords
RP-HPLC, Hydrochlorothiazide and Amlodipine., Olmesartan, method development
References
Bangalore S.,Kamalakkannan G Fau - Parkar S.,Parkar S Fau - Messerli F. H.,Messerli F. H. .2007 .Fixed-dose combinations improve medication compliance: a metaanalysis. Am J Med, 120 : 713-719.
.2005 .. , 116 : 117.
United States Pharmacopeial Convention .2015 .. , : .
Stumpe K. O. .2004 .Olmesartan compared with other angiotensin II receptor antagonists: head-to-head trials. Clinical Therapeutics, 26 : 33-37.
United States Pharmacopeial Convention .2015 .. , : .
Carter B. L.,Ernst M. E.,Cohen J. D.,Hydrochlorothiazide Versus J. D.,E J. D. .2004 .Chlorthalidone. Hypertension, 0000103632 : 4-9.
United States Pharmacopeial Convention .2015 .. , : .
Li Y. R. .2015 .CardiovasCular diseases: From Molecular Pharmacology to evidence‐Based Therapeutics. , 189 : .
Sheikh M.,Annadi A.,Mohamed A. .2018 .A Novel RP-HPLC Method for the Simultaneous Assessment of Olmesartan, Amlodipine and Hydrochlorothiazide and its Application to Invitro Dissolution. Der Pharma Chemica, 10 : 55-61.
Jain P.,Patel M. K.,Gorle A. P.,Chaudhari A.,Surana S. .2012 .Stability-Indicating Method for Simultaneous Estimation of Olmesartan Medoxomile, Amlodipine Besylate and Hydrochlorothiazide by RP-HPLC in Tablet Dosage Form. Journal of chromatographic science 50, : 680-687.
Qutab S.,Razzaq D. S. N.,Ashfaq M.,Khan I.,Mumtaz A. M. .2009 .Simultaneous quantitation of Olmesartan Medoxomil and Amlodipine Besylate in combined tablets using HPLC. Journal of the Chilean Chemical Society, 54 : 234-237.
Kumar D.,Panda S.,Sahoo S. .2019 .Development of Stability Indicating RP-HPLC Method for Simultaneous Estimation of Amlodipine and Olmesartan in Pure and Pharmaceutical Dosage Form. International Journal of Pharmaceutical Quality Assurance, 10(4) : .
Manoharan G.,Al-Bratty M.,Alhazmi H. Development .2016 .and validation of reversedphase HPLC techniques for simultaneous estimation of amlodipine, hydrochlorothiazide and olmesartan in raw and tablet formulation. International Journal of Pharmaceutical Sciences Review and Research, 38 : 205-209.
Pandya G.,Joshi H. Development .2013 .and validation of stability indicating HPLC assay method for simultaneous determination of Amlodepine besylate, olmesartan medoxomil and hydrochlorothiazide in tablet formulation. Der Phamacia Sinica, 4 : .
Napoleon A.,Angajala G.,A G.,R. G. .2015 .HPLC method development and validation for simultaneous estimation of Olmesartan Medoxomil, Hydrochlorothiazide and Amlodipine Besylate tablets. Der Pharmacia Lettre, 7 : 182-196.
Patchala A.,Nadendla R. .2020 .Quantification and validation of amlodipine besylate, olmesartan medoxomil and hydrochlorothiazide by rp-hplc in marketed dosage form. International Journal of Pharmaceutical Sciences and Research, 11 : 2350-2355.
Moffat A. C. .2011 .Clarke's Analysis of Drugs and Poisons. 4th edn, : .
Dolan ,North America .2003 .. , 10(LCGC) : 968-972.
.2005 .(International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human use. , : .
Ferreira S. L. C.,Caires A. O.,Fau - Borges S.,Borges T. da S.,Fau - Lima A. M. D. S.,Lima A. M. D. S. Fau - Silva L. O. B.,Silva L. O. B. Fau - dos Santos W. N. L.,dos Santos W. N. L. .2017 .Robustness evaluation in analytical methods optimized using experimental designs. Microchem J, 131 : 163-169.
Heyden Vander,Nijhuis Y.,SmeyersVerbeke J Fau - Vandeginste A Fau.,Massart B. G. M. .2001 .Guidance for robustness/ruggedness tests in method validation. J Pharm Biomed Anal, 24 : 723-753.
0

Citations

0

Downloads

7

Views